Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
One cause of relapse in cancer patients treated with chimeric antigen receptor (CAR) T cells is the loss of CAR-targeted antigens, which is particularly common in multiple myeloma (MM). Here the authors engineer a CAR recognizing two common MM-associated antigens and demonstrate its superiority to s...
Guardado en:
Autores principales: | Eugenia Zah, Eunwoo Nam, Vinya Bhuvan, Uyen Tran, Brenda Y. Ji, Stanley B. Gosliner, Xiuli Wang, Christine E. Brown, Yvonne Y. Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec2f088f8b5544bbb62387a290932f01 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Mehmet Kemal Samur, et al.
Publicado: (2021) -
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Yiyun Wang, et al.
Publicado: (2021) -
Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Chetan Rathi, et al.
Publicado: (2021) -
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Barbara Savoldo, et al.
Publicado: (2021) -
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
por: Enrique J. Arenas, et al.
Publicado: (2021)